| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes, Gestational | 62 | 2026 | 328 | 9.800 |
Why?
|
| Autism Spectrum Disorder | 18 | 2025 | 164 | 6.730 |
Why?
|
| Diabetes Mellitus, Type 2 | 55 | 2026 | 689 | 6.560 |
Why?
|
| Insulin Resistance | 36 | 2025 | 128 | 5.650 |
Why?
|
| Air Pollution | 11 | 2024 | 47 | 5.450 |
Why?
|
| Air Pollutants | 12 | 2024 | 59 | 5.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 16 | 2026 | 205 | 4.300 |
Why?
|
| Insulin-Secreting Cells | 13 | 2018 | 18 | 3.890 |
Why?
|
| Pregnancy | 85 | 2026 | 1565 | 3.800 |
Why?
|
| Insulin | 40 | 2026 | 188 | 3.460 |
Why?
|
| Humans | 178 | 2026 | 17622 | 3.180 |
Why?
|
| Female | 147 | 2026 | 12715 | 3.120 |
Why?
|
| Hypoglycemic Agents | 23 | 2025 | 259 | 2.980 |
Why?
|
| Blood Glucose | 39 | 2026 | 319 | 2.780 |
Why?
|
| Mexican Americans | 18 | 2019 | 43 | 2.380 |
Why?
|
| Pregnancy in Diabetics | 8 | 2018 | 18 | 2.330 |
Why?
|
| Body Mass Index | 29 | 2025 | 959 | 2.290 |
Why?
|
| Hispanic Americans | 33 | 2019 | 370 | 2.260 |
Why?
|
| Adult | 95 | 2026 | 7621 | 2.250 |
Why?
|
| Male | 88 | 2026 | 10014 | 2.200 |
Why?
|
| Particulate Matter | 11 | 2026 | 36 | 2.060 |
Why?
|
| Thiazolidinediones | 13 | 2013 | 50 | 1.940 |
Why?
|
| Weight Gain | 6 | 2019 | 165 | 1.840 |
Why?
|
| Maternal Exposure | 9 | 2026 | 84 | 1.830 |
Why?
|
| Child, Preschool | 22 | 2026 | 1455 | 1.810 |
Why?
|
| Breast Feeding | 6 | 2025 | 119 | 1.770 |
Why?
|
| Autistic Disorder | 6 | 2026 | 115 | 1.730 |
Why?
|
| Child | 30 | 2026 | 2485 | 1.710 |
Why?
|
| Cohort Studies | 36 | 2025 | 2502 | 1.590 |
Why?
|
| Retrospective Studies | 30 | 2026 | 2502 | 1.580 |
Why?
|
| Glucose Tolerance Test | 33 | 2025 | 108 | 1.560 |
Why?
|
| Obesity | 17 | 2025 | 821 | 1.520 |
Why?
|
| Analgesia, Epidural | 2 | 2023 | 4 | 1.460 |
Why?
|
| Labor, Obstetric | 2 | 2023 | 5 | 1.460 |
Why?
|
| Metformin | 5 | 2022 | 52 | 1.450 |
Why?
|
| Environmental Pollutants | 2 | 2023 | 67 | 1.420 |
Why?
|
| Multiple Sclerosis | 6 | 2020 | 102 | 1.420 |
Why?
|
| Adiposity | 7 | 2019 | 71 | 1.390 |
Why?
|
| Polymorphism, Single Nucleotide | 21 | 2025 | 369 | 1.390 |
Why?
|
| Depression | 3 | 2024 | 507 | 1.380 |
Why?
|
| California | 28 | 2026 | 2433 | 1.370 |
Why?
|
| Overweight | 6 | 2022 | 266 | 1.280 |
Why?
|
| Hypertension | 10 | 2023 | 486 | 1.200 |
Why?
|
| Environmental Exposure | 8 | 2025 | 123 | 1.170 |
Why?
|
| Risk Factors | 40 | 2026 | 3291 | 1.130 |
Why?
|
| Adipokines | 2 | 2018 | 4 | 1.120 |
Why?
|
| Asthma | 2 | 2023 | 401 | 1.110 |
Why?
|
| Mothers | 5 | 2023 | 105 | 1.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2019 | 70 | 1.090 |
Why?
|
| Glucose Intolerance | 8 | 2022 | 46 | 1.080 |
Why?
|
| Adolescent | 23 | 2025 | 3625 | 1.040 |
Why?
|
| Pre-Eclampsia | 3 | 2024 | 41 | 0.980 |
Why?
|
| Hepatitis B virus | 5 | 2020 | 21 | 0.960 |
Why?
|
| Young Adult | 23 | 2025 | 2538 | 0.930 |
Why?
|
| Exercise Therapy | 4 | 2019 | 75 | 0.900 |
Why?
|
| European Continental Ancestry Group | 9 | 2021 | 470 | 0.890 |
Why?
|
| Longitudinal Studies | 12 | 2025 | 686 | 0.870 |
Why?
|
| Nitrogen Dioxide | 4 | 2023 | 17 | 0.870 |
Why?
|
| Gastroplasty | 3 | 2022 | 10 | 0.860 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2019 | 184 | 0.840 |
Why?
|
| C-Reactive Protein | 2 | 2018 | 56 | 0.840 |
Why?
|
| Immunoassay | 2 | 2014 | 9 | 0.830 |
Why?
|
| Prediabetic State | 3 | 2025 | 62 | 0.800 |
Why?
|
| Anxiety | 1 | 2024 | 162 | 0.790 |
Why?
|
| Middle Aged | 43 | 2025 | 7954 | 0.780 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 109 | 0.780 |
Why?
|
| Awards and Prizes | 1 | 2023 | 9 | 0.770 |
Why?
|
| Chromans | 9 | 2007 | 9 | 0.770 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 1157 | 0.740 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2025 | 384 | 0.730 |
Why?
|
| Mentoring | 2 | 2019 | 29 | 0.720 |
Why?
|
| Incidence | 12 | 2026 | 1278 | 0.720 |
Why?
|
| Genetic Variation | 11 | 2017 | 82 | 0.720 |
Why?
|
| Hypothalamus | 3 | 2025 | 4 | 0.710 |
Why?
|
| Genome-Wide Association Study | 12 | 2025 | 255 | 0.690 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2018 | 120 | 0.690 |
Why?
|
| Islets of Langerhans | 8 | 2024 | 11 | 0.690 |
Why?
|
| Pancreatitis | 1 | 2022 | 54 | 0.680 |
Why?
|
| Aged | 28 | 2025 | 6223 | 0.680 |
Why?
|
| Ozone | 3 | 2019 | 14 | 0.680 |
Why?
|
| Body Weight | 7 | 2025 | 203 | 0.660 |
Why?
|
| Cell Separation | 1 | 2020 | 1 | 0.640 |
Why?
|
| Filtration | 1 | 2020 | 1 | 0.640 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 1 | 0.640 |
Why?
|
| Parents | 2 | 2019 | 301 | 0.640 |
Why?
|
| African Continental Ancestry Group | 3 | 2018 | 140 | 0.630 |
Why?
|
| PPAR gamma | 4 | 2015 | 9 | 0.630 |
Why?
|
| Leptin | 2 | 2018 | 26 | 0.620 |
Why?
|
| Blood Pressure | 11 | 2026 | 288 | 0.620 |
Why?
|
| Hospitalization | 3 | 2023 | 831 | 0.620 |
Why?
|
| Mass Screening | 2 | 2024 | 693 | 0.620 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 42 | 0.610 |
Why?
|
| Glucose | 6 | 2023 | 30 | 0.600 |
Why?
|
| Child of Impaired Parents | 1 | 2019 | 27 | 0.590 |
Why?
|
| Hippocampus | 4 | 2024 | 8 | 0.580 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2024 | 540 | 0.570 |
Why?
|
| Disease Progression | 6 | 2024 | 266 | 0.570 |
Why?
|
| Pediatric Obesity | 3 | 2024 | 101 | 0.560 |
Why?
|
| Exercise | 8 | 2025 | 538 | 0.560 |
Why?
|
| Postpartum Period | 6 | 2025 | 93 | 0.560 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 402 | 0.560 |
Why?
|
| Diet | 5 | 2026 | 355 | 0.560 |
Why?
|
| Hepatitis B Core Antigens | 2 | 2015 | 2 | 0.550 |
Why?
|
| Viral Core Proteins | 2 | 2015 | 2 | 0.550 |
Why?
|
| Interleukin-6 | 1 | 2018 | 24 | 0.550 |
Why?
|
| Diabetes Mellitus | 6 | 2025 | 452 | 0.540 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 2 | 0.530 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 6 | 0.530 |
Why?
|
| Infant | 5 | 2023 | 1228 | 0.530 |
Why?
|
| Arginine | 2 | 2014 | 12 | 0.530 |
Why?
|
| Infant, Newborn | 13 | 2024 | 842 | 0.530 |
Why?
|
| Energy Intake | 2 | 2014 | 97 | 0.520 |
Why?
|
| Antibodies, Viral | 1 | 2017 | 73 | 0.510 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2015 | 2 | 0.480 |
Why?
|
| Hepatitis B | 2 | 2013 | 41 | 0.470 |
Why?
|
| Motor Activity | 3 | 2015 | 207 | 0.460 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 1 | 0.460 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 2 | 0.450 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 4 | 0.450 |
Why?
|
| Cues | 2 | 2025 | 9 | 0.440 |
Why?
|
| Brain | 2 | 2025 | 50 | 0.430 |
Why?
|
| Oceanic Ancestry Group | 1 | 2014 | 32 | 0.430 |
Why?
|
| Aptamers, Nucleotide | 1 | 2014 | 1 | 0.430 |
Why?
|
| Microcystins | 1 | 2014 | 1 | 0.430 |
Why?
|
| Water Pollutants, Chemical | 1 | 2014 | 6 | 0.430 |
Why?
|
| Leucine | 1 | 2014 | 4 | 0.430 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2014 | 87 | 0.420 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2013 | 14 | 0.420 |
Why?
|
| DNA, Viral | 3 | 2020 | 17 | 0.420 |
Why?
|
| Health Status Disparities | 2 | 2014 | 151 | 0.410 |
Why?
|
| Arteriosclerosis | 2 | 2004 | 16 | 0.410 |
Why?
|
| Adiponectin | 3 | 2010 | 21 | 0.400 |
Why?
|
| Prevalence | 4 | 2024 | 830 | 0.400 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 1 | 0.400 |
Why?
|
| Diet, High-Fat | 1 | 2013 | 5 | 0.390 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2025 | 107 | 0.380 |
Why?
|
| Animals | 12 | 2024 | 285 | 0.370 |
Why?
|
| Cholesterol, LDL | 6 | 2016 | 117 | 0.370 |
Why?
|
| Tunica Intima | 4 | 2009 | 10 | 0.360 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2024 | 7 | 0.360 |
Why?
|
| Vehicle Emissions | 3 | 2024 | 23 | 0.360 |
Why?
|
| Logistic Models | 4 | 2019 | 866 | 0.350 |
Why?
|
| United States | 8 | 2024 | 3922 | 0.350 |
Why?
|
| Genotype | 8 | 2020 | 224 | 0.350 |
Why?
|
| Glucose Clamp Technique | 10 | 2014 | 17 | 0.350 |
Why?
|
| Patient Selection | 3 | 2025 | 181 | 0.340 |
Why?
|
| Severity of Illness Index | 3 | 2022 | 446 | 0.340 |
Why?
|
| Time Factors | 12 | 2026 | 1038 | 0.340 |
Why?
|
| Carotid Artery Diseases | 2 | 2007 | 11 | 0.340 |
Why?
|
| Triglycerides | 6 | 2025 | 81 | 0.340 |
Why?
|
| Obstetric Labor Complications | 2 | 2017 | 11 | 0.330 |
Why?
|
| Mice | 10 | 2024 | 82 | 0.330 |
Why?
|
| Contraceptives, Oral | 3 | 2007 | 25 | 0.330 |
Why?
|
| Absorptiometry, Photon | 5 | 2015 | 54 | 0.330 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2011 | 15 | 0.320 |
Why?
|
| Membrane Proteins | 3 | 2025 | 39 | 0.320 |
Why?
|
| Cholesterol, HDL | 6 | 2025 | 68 | 0.310 |
Why?
|
| Lipids | 2 | 2025 | 69 | 0.310 |
Why?
|
| Risk | 4 | 2017 | 492 | 0.310 |
Why?
|
| Mutation | 2 | 2020 | 133 | 0.300 |
Why?
|
| Risk Assessment | 7 | 2026 | 1093 | 0.300 |
Why?
|
| Cross-Sectional Studies | 6 | 2026 | 1295 | 0.290 |
Why?
|
| Thiazoles | 5 | 2018 | 10 | 0.290 |
Why?
|
| Pregnancy Complications | 3 | 2020 | 208 | 0.290 |
Why?
|
| Body Composition | 4 | 2014 | 92 | 0.290 |
Why?
|
| Mitochondrial Proteins | 2 | 2019 | 4 | 0.280 |
Why?
|
| Peptides | 2 | 2019 | 14 | 0.280 |
Why?
|
| HLA-DRB1 Chains | 2 | 2019 | 12 | 0.280 |
Why?
|
| Food | 2 | 2025 | 36 | 0.270 |
Why?
|
| Sunlight | 2 | 2018 | 13 | 0.270 |
Why?
|
| Socioeconomic Factors | 4 | 2017 | 603 | 0.270 |
Why?
|
| Electric Impedance | 3 | 2014 | 7 | 0.270 |
Why?
|
| Proportional Hazards Models | 8 | 2019 | 702 | 0.270 |
Why?
|
| Medroxyprogesterone | 1 | 2007 | 2 | 0.260 |
Why?
|
| High-Throughput Screening Assays | 2 | 2020 | 6 | 0.260 |
Why?
|
| Homeostasis | 3 | 2016 | 11 | 0.260 |
Why?
|
| Carotid Arteries | 3 | 2009 | 8 | 0.260 |
Why?
|
| Vitamin D | 2 | 2018 | 76 | 0.260 |
Why?
|
| Cell Line, Tumor | 4 | 2020 | 11 | 0.260 |
Why?
|
| Walking | 2 | 2019 | 89 | 0.250 |
Why?
|
| Amino Acids | 1 | 2026 | 5 | 0.240 |
Why?
|
| Fatty Acids | 1 | 2026 | 9 | 0.240 |
Why?
|
| African Americans | 5 | 2019 | 429 | 0.240 |
Why?
|
| Extreme Heat | 1 | 2026 | 3 | 0.240 |
Why?
|
| Wildfires | 1 | 2026 | 2 | 0.240 |
Why?
|
| Metabolic Syndrome | 3 | 2015 | 64 | 0.230 |
Why?
|
| Endocrine Disruptors | 1 | 2025 | 9 | 0.230 |
Why?
|
| Biomarkers | 3 | 2026 | 302 | 0.230 |
Why?
|
| Phenotype | 11 | 2014 | 154 | 0.230 |
Why?
|
| Non-Nutritive Sweeteners | 1 | 2025 | 1 | 0.230 |
Why?
|
| Sucrose | 1 | 2025 | 6 | 0.230 |
Why?
|
| Appetite Regulation | 1 | 2025 | 5 | 0.230 |
Why?
|
| Fluorocarbons | 1 | 2025 | 20 | 0.230 |
Why?
|
| Sweetening Agents | 1 | 2025 | 9 | 0.220 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2021 | 7 | 0.220 |
Why?
|
| Pandemics | 2 | 2024 | 295 | 0.220 |
Why?
|
| Diabetes Complications | 1 | 2025 | 103 | 0.220 |
Why?
|
| RNA-Binding Proteins | 2 | 2018 | 6 | 0.210 |
Why?
|
| Quality of Life | 3 | 2019 | 505 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 168 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 323 | 0.210 |
Why?
|
| Genome, Mitochondrial | 1 | 2024 | 2 | 0.210 |
Why?
|
| Models, Statistical | 1 | 2025 | 171 | 0.200 |
Why?
|
| Caveolin 1 | 2 | 2015 | 2 | 0.200 |
Why?
|
| Cesarean Section | 1 | 2004 | 35 | 0.200 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2020 | 22 | 0.200 |
Why?
|
| Obesity, Morbid | 2 | 2017 | 121 | 0.200 |
Why?
|
| Aircraft | 1 | 2023 | 3 | 0.200 |
Why?
|
| Oxytocin | 1 | 2023 | 4 | 0.200 |
Why?
|
| Transcription Factors | 2 | 2024 | 21 | 0.200 |
Why?
|
| Analgesics | 1 | 2023 | 27 | 0.200 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 262 | 0.200 |
Why?
|
| Gestational Age | 3 | 2020 | 119 | 0.200 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 36 | 0.200 |
Why?
|
| Carbon | 1 | 2023 | 3 | 0.190 |
Why?
|
| Manganese | 1 | 2023 | 3 | 0.190 |
Why?
|
| Vitamins | 1 | 2023 | 59 | 0.190 |
Why?
|
| Streptococcal Infections | 1 | 2023 | 23 | 0.190 |
Why?
|
| Fasting | 7 | 2013 | 46 | 0.190 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 6 | 0.190 |
Why?
|
| Pregnancy Trimester, First | 2 | 2019 | 43 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2019 | 1161 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 3 | 2012 | 15 | 0.180 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 104 | 0.180 |
Why?
|
| Environmental Monitoring | 2 | 2019 | 27 | 0.180 |
Why?
|
| Acute Disease | 1 | 2022 | 147 | 0.170 |
Why?
|
| Case-Control Studies | 4 | 2018 | 1107 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 152 | 0.170 |
Why?
|
| Regression Analysis | 5 | 2025 | 268 | 0.170 |
Why?
|
| Smad2 Protein | 1 | 2020 | 1 | 0.170 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2020 | 1 | 0.170 |
Why?
|
| Oligopeptides | 1 | 2020 | 6 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2020 | 5 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 4 | 0.170 |
Why?
|
| Pulmonary Fibrosis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 1976 | 0.170 |
Why?
|
| Kidney | 2 | 2019 | 52 | 0.170 |
Why?
|
| Maternal Age | 1 | 2020 | 74 | 0.160 |
Why?
|
| Self Report | 2 | 2019 | 262 | 0.160 |
Why?
|
| Lung | 1 | 2020 | 57 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2026 | 1251 | 0.160 |
Why?
|
| Vibration | 1 | 2020 | 1 | 0.160 |
Why?
|
| Electromagnetic Phenomena | 1 | 2020 | 1 | 0.160 |
Why?
|
| Equipment Design | 1 | 2020 | 7 | 0.160 |
Why?
|
| Cell Count | 1 | 2020 | 11 | 0.160 |
Why?
|
| Fructose | 1 | 2020 | 6 | 0.160 |
Why?
|
| Dietary Sugars | 1 | 2020 | 6 | 0.160 |
Why?
|
| Social Support | 2 | 2019 | 215 | 0.160 |
Why?
|
| Dietary Proteins | 2 | 2026 | 20 | 0.160 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 100 | 0.160 |
Why?
|
| APOBEC-1 Deaminase | 1 | 2019 | 1 | 0.150 |
Why?
|
| Glycated Hemoglobin A | 5 | 2021 | 179 | 0.150 |
Why?
|
| Lipase | 1 | 2019 | 2 | 0.150 |
Why?
|
| Aspartate Aminotransferases | 1 | 2019 | 10 | 0.150 |
Why?
|
| Alanine Transaminase | 1 | 2019 | 19 | 0.150 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2001 | 8 | 0.150 |
Why?
|
| C-Peptide | 3 | 2017 | 6 | 0.150 |
Why?
|
| Galactose | 1 | 2019 | 1 | 0.150 |
Why?
|
| Pregnancy Trimesters | 2 | 2019 | 29 | 0.150 |
Why?
|
| Fetal Development | 1 | 2019 | 15 | 0.150 |
Why?
|
| Genome, Human | 3 | 2021 | 33 | 0.150 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 2 | 2017 | 11 | 0.150 |
Why?
|
| Kidney Calculi | 1 | 2019 | 6 | 0.150 |
Why?
|
| Genetic Linkage | 3 | 2012 | 7 | 0.150 |
Why?
|
| Alleles | 4 | 2021 | 80 | 0.150 |
Why?
|
| Cholesterol | 2 | 2010 | 82 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2024 | 729 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2019 | 631 | 0.140 |
Why?
|
| Amino Acid Substitution | 3 | 2015 | 7 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 20 | 0.140 |
Why?
|
| Life Style | 1 | 2020 | 321 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2018 | 9 | 0.140 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 3 | 0.140 |
Why?
|
| Adipogenesis | 1 | 2018 | 4 | 0.140 |
Why?
|
| Osteogenesis | 1 | 2018 | 3 | 0.140 |
Why?
|
| Amides | 1 | 2018 | 4 | 0.140 |
Why?
|
| Sex Factors | 5 | 2020 | 599 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 158 | 0.140 |
Why?
|
| Hepatocytes | 2 | 2015 | 3 | 0.140 |
Why?
|
| Fatty Acids, Nonesterified | 4 | 2009 | 12 | 0.140 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2018 | 4 | 0.140 |
Why?
|
| Reference Values | 2 | 2013 | 86 | 0.140 |
Why?
|
| Tunica Media | 3 | 2009 | 6 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 50 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 1 | 0.140 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2018 | 65 | 0.140 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 61 | 0.140 |
Why?
|
| Estrogen Receptor beta | 1 | 2017 | 10 | 0.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 7 | 0.140 |
Why?
|
| Anthropometry | 3 | 2015 | 59 | 0.130 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 15 | 0.130 |
Why?
|
| Liver | 4 | 2024 | 31 | 0.130 |
Why?
|
| Vitamin D Deficiency | 1 | 2018 | 24 | 0.130 |
Why?
|
| Hygiene | 1 | 2017 | 2 | 0.130 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2017 | 2 | 0.130 |
Why?
|
| Exosomes | 1 | 2017 | 2 | 0.130 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 26 | 0.130 |
Why?
|
| Hypoxia | 1 | 2017 | 8 | 0.130 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 5 | 0.130 |
Why?
|
| Reproductive Physiological Phenomena | 1 | 2017 | 3 | 0.130 |
Why?
|
| Emigrants and Immigrants | 1 | 2017 | 27 | 0.130 |
Why?
|
| Asphyxia | 1 | 2017 | 3 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2017 | 12 | 0.130 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2017 | 9 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 57 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 187 | 0.120 |
Why?
|
| Proline | 2 | 2015 | 5 | 0.120 |
Why?
|
| Pregnancy Trimester, Third | 3 | 2026 | 22 | 0.120 |
Why?
|
| Alanine | 2 | 2015 | 8 | 0.120 |
Why?
|
| Myogenin | 1 | 2016 | 1 | 0.120 |
Why?
|
| PAX7 Transcription Factor | 1 | 2016 | 1 | 0.120 |
Why?
|
| Myogenic Regulatory Factor 5 | 1 | 2016 | 1 | 0.120 |
Why?
|
| Myostatin | 1 | 2016 | 1 | 0.120 |
Why?
|
| Premenopause | 2 | 2007 | 24 | 0.120 |
Why?
|
| Cattle | 1 | 2016 | 10 | 0.120 |
Why?
|
| Diet, Diabetic | 3 | 1998 | 7 | 0.120 |
Why?
|
| Quantitative Trait Loci | 3 | 2025 | 38 | 0.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 22 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 1296 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 36 | 0.120 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2015 | 1 | 0.120 |
Why?
|
| Ethnic Groups | 2 | 2019 | 443 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 144 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 2 | 0.110 |
Why?
|
| Premature Birth | 1 | 2017 | 136 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 71 | 0.110 |
Why?
|
| Complement Activation | 1 | 2015 | 1 | 0.110 |
Why?
|
| Lectins | 1 | 2015 | 1 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2015 | 2 | 0.110 |
Why?
|
| Complement System Proteins | 1 | 2015 | 4 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 9 | 0.110 |
Why?
|
| Vincristine | 1 | 1994 | 1 | 0.110 |
Why?
|
| Prednisone | 1 | 1994 | 6 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1994 | 8 | 0.110 |
Why?
|
| Adipose Tissue | 3 | 2009 | 67 | 0.110 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 1 | 0.110 |
Why?
|
| Horseradish Peroxidase | 1 | 2014 | 1 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 4 | 0.110 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2014 | 2 | 0.110 |
Why?
|
| Bariatric Surgery | 1 | 2017 | 133 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 22 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2014 | 61 | 0.110 |
Why?
|
| Receptor, Melatonin, MT2 | 1 | 2014 | 1 | 0.110 |
Why?
|
| Metabolic Clearance Rate | 1 | 2014 | 4 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2015 | 75 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 25 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 102 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 226 | 0.100 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Liraglutide | 1 | 2013 | 3 | 0.100 |
Why?
|
| Waist-Hip Ratio | 2 | 2011 | 23 | 0.100 |
Why?
|
| Research Design | 2 | 1999 | 337 | 0.100 |
Why?
|
| Gastrectomy | 1 | 2014 | 46 | 0.100 |
Why?
|
| Likelihood Functions | 2 | 2025 | 45 | 0.100 |
Why?
|
| Congenital Abnormalities | 3 | 2000 | 27 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2014 | 46 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 190 | 0.100 |
Why?
|
| Stroke | 1 | 2016 | 309 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2013 | 20 | 0.100 |
Why?
|
| Dietary Carbohydrates | 1 | 2013 | 28 | 0.100 |
Why?
|
| Gastric Bypass | 1 | 2014 | 70 | 0.100 |
Why?
|
| Inflammation | 2 | 2024 | 60 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 363 | 0.090 |
Why?
|
| Multifactorial Inheritance | 2 | 2024 | 23 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2013 | 85 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 302 | 0.090 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 23 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2012 | 1 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2012 | 6 | 0.090 |
Why?
|
| Postnatal Care | 1 | 2012 | 20 | 0.090 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2012 | 2 | 0.090 |
Why?
|
| Age Factors | 3 | 2017 | 874 | 0.090 |
Why?
|
| Histone Demethylases | 1 | 2012 | 3 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2014 | 163 | 0.090 |
Why?
|
| Prenatal Care | 2 | 2012 | 129 | 0.090 |
Why?
|
| Progestins | 2 | 2010 | 25 | 0.090 |
Why?
|
| Genetic Association Studies | 3 | 2017 | 33 | 0.090 |
Why?
|
| Contraceptive Agents, Female | 1 | 2011 | 12 | 0.090 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 2 | 2007 | 4 | 0.090 |
Why?
|
| Intra-Abdominal Fat | 1 | 2011 | 17 | 0.080 |
Why?
|
| Waist Circumference | 1 | 2011 | 34 | 0.080 |
Why?
|
| Survival Rate | 3 | 2016 | 252 | 0.080 |
Why?
|
| Contraception | 1 | 2010 | 23 | 0.080 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2009 | 2 | 0.080 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2009 | 3 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2009 | 1 | 0.080 |
Why?
|
| Placebos | 2 | 2007 | 19 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 32 | 0.080 |
Why?
|
| Surgical Staplers | 1 | 2009 | 1 | 0.080 |
Why?
|
| Electrocoagulation | 1 | 2009 | 3 | 0.080 |
Why?
|
| Leg | 1 | 2009 | 3 | 0.080 |
Why?
|
| Blood Loss, Surgical | 1 | 2009 | 3 | 0.080 |
Why?
|
| Thigh | 1 | 2009 | 11 | 0.080 |
Why?
|
| Amputation | 1 | 2009 | 10 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2018 | 33 | 0.070 |
Why?
|
| Calpain | 1 | 2009 | 1 | 0.070 |
Why?
|
| Genetic Loci | 2 | 2019 | 54 | 0.070 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2008 | 1 | 0.070 |
Why?
|
| Haplotypes | 3 | 2019 | 34 | 0.070 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2006 | 5 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2018 | 19 | 0.070 |
Why?
|
| Hypertension, Renal | 1 | 2007 | 4 | 0.070 |
Why?
|
| Linear Models | 2 | 2019 | 204 | 0.070 |
Why?
|
| Pedigree | 2 | 2014 | 65 | 0.070 |
Why?
|
| Hyperinsulinism | 2 | 2001 | 8 | 0.070 |
Why?
|
| Genotyping Techniques | 2 | 2018 | 26 | 0.070 |
Why?
|
| Albuminuria | 1 | 2007 | 39 | 0.070 |
Why?
|
| TCF Transcription Factors | 1 | 2007 | 9 | 0.060 |
Why?
|
| Safety | 1 | 2007 | 43 | 0.060 |
Why?
|
| Apoptosis | 2 | 2018 | 11 | 0.060 |
Why?
|
| Parity | 4 | 2005 | 57 | 0.060 |
Why?
|
| Metabolomics | 1 | 2026 | 9 | 0.060 |
Why?
|
| Weight Loss | 2 | 2022 | 298 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2025 | 719 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2017 | 214 | 0.060 |
Why?
|
| Pesticides | 1 | 2025 | 8 | 0.060 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2025 | 6 | 0.060 |
Why?
|
| Halogenated Diphenyl Ethers | 1 | 2025 | 10 | 0.060 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2025 | 12 | 0.060 |
Why?
|
| Australia | 1 | 2025 | 26 | 0.060 |
Why?
|
| Proteomics | 1 | 2025 | 10 | 0.060 |
Why?
|
| Hunger | 1 | 2025 | 4 | 0.060 |
Why?
|
| Neural Pathways | 1 | 2025 | 2 | 0.060 |
Why?
|
| Brain Mapping | 1 | 2025 | 4 | 0.060 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2025 | 26 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2025 | 50 | 0.060 |
Why?
|
| Sleep | 1 | 2025 | 56 | 0.060 |
Why?
|
| Accelerometry | 1 | 2025 | 57 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2025 | 73 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 85 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2024 | 5 | 0.050 |
Why?
|
| Telephone | 1 | 2025 | 159 | 0.050 |
Why?
|
| Enteroendocrine Cells | 1 | 2024 | 1 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2024 | 2 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 2 | 0.050 |
Why?
|
| Adipocytes | 1 | 2024 | 4 | 0.050 |
Why?
|
| Chromatin | 1 | 2024 | 6 | 0.050 |
Why?
|
| Epigenomics | 1 | 2024 | 6 | 0.050 |
Why?
|
| Fibrosis | 1 | 2024 | 6 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 2 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 4 | 0.050 |
Why?
|
| Protein Binding | 2 | 2015 | 10 | 0.050 |
Why?
|
| Peripheral Arterial Disease | 1 | 2024 | 14 | 0.050 |
Why?
|
| Diabetic Nephropathies | 1 | 2024 | 25 | 0.050 |
Why?
|
| Streptococcus agalactiae | 1 | 2023 | 9 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2023 | 14 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2024 | 112 | 0.050 |
Why?
|
| Gliosis | 1 | 2022 | 1 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2022 | 3 | 0.050 |
Why?
|
| Recurrence | 2 | 2020 | 166 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2002 | 2 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2024 | 169 | 0.050 |
Why?
|
| Puerperal Disorders | 1 | 2002 | 8 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2001 | 3 | 0.040 |
Why?
|
| Physical Chromosome Mapping | 1 | 2021 | 1 | 0.040 |
Why?
|
| Texas | 2 | 2014 | 41 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 142 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 37 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2002 | 145 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 2020 | 1 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2020 | 5 | 0.040 |
Why?
|
| Actins | 1 | 2020 | 3 | 0.040 |
Why?
|
| Collagen | 1 | 2020 | 8 | 0.040 |
Why?
|
| Virus Replication | 1 | 2020 | 12 | 0.040 |
Why?
|
| Rats | 1 | 2020 | 33 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2020 | 5 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 527 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2001 | 174 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2001 | 90 | 0.040 |
Why?
|
| Age Distribution | 1 | 2001 | 230 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 17 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2020 | 56 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 16 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2013 | 28 | 0.040 |
Why?
|
| DNA Primers | 2 | 2013 | 8 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 51 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 32 | 0.040 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2019 | 3 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 3 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 13 | 0.040 |
Why?
|
| Mitochondria | 1 | 2019 | 7 | 0.040 |
Why?
|
| HLA-A3 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
| HLA-B7 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
| Models, Biological | 1 | 1999 | 27 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 1 | 0.040 |
Why?
|
| Histone Code | 1 | 2019 | 1 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 1999 | 38 | 0.040 |
Why?
|
| Intrauterine Devices, Copper | 2 | 1998 | 5 | 0.040 |
Why?
|
| Patient Education as Topic | 2 | 2015 | 193 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 1998 | 4 | 0.040 |
Why?
|
| Fetus | 1 | 1998 | 5 | 0.040 |
Why?
|
| Gravidity | 1 | 1998 | 5 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 1999 | 66 | 0.040 |
Why?
|
| Body Constitution | 1 | 1998 | 39 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2018 | 1 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 1 | 0.030 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2018 | 2 | 0.030 |
Why?
|
| Public Health | 1 | 1999 | 84 | 0.030 |
Why?
|
| Anilides | 1 | 2018 | 3 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2018 | 3 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2009 | 34 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 4 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2018 | 1 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 11 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2018 | 14 | 0.030 |
Why?
|
| Nitriles | 1 | 2018 | 8 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 3 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2018 | 6 | 0.030 |
Why?
|
| beta Catenin | 1 | 2018 | 2 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2011 | 14 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1998 | 100 | 0.030 |
Why?
|
| Asian Americans | 1 | 2019 | 160 | 0.030 |
Why?
|
| Colorado | 2 | 2014 | 170 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 4 | 0.030 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2017 | 3 | 0.030 |
Why?
|
| Macrophages | 1 | 2017 | 8 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 159 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 10 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2017 | 2 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 2 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 5 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 30 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 85 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 1995 | 137 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 80 | 0.030 |
Why?
|
| Apgar Score | 1 | 2017 | 5 | 0.030 |
Why?
|
| Pravastatin | 1 | 2016 | 2 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2016 | 4 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2016 | 6 | 0.030 |
Why?
|
| Lovastatin | 1 | 2016 | 7 | 0.030 |
Why?
|
| Simvastatin | 1 | 2016 | 12 | 0.030 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1996 | 2 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 1996 | 12 | 0.030 |
Why?
|
| Myocardium | 1 | 1996 | 6 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1996 | 4 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2016 | 9 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 60 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 43 | 0.030 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1995 | 15 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 143 | 0.030 |
Why?
|
| Pregnancy Outcome | 2 | 2010 | 162 | 0.030 |
Why?
|
| Spirometry | 1 | 2015 | 59 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 69 | 0.030 |
Why?
|
| Motor Vehicles | 1 | 2015 | 1 | 0.030 |
Why?
|
| Pelvic Bones | 1 | 2015 | 4 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 1 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2015 | 1 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 2 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 4 | 0.030 |
Why?
|
| Serum | 1 | 2015 | 4 | 0.030 |
Why?
|
| Genome | 1 | 2014 | 4 | 0.030 |
Why?
|
| Motivation | 1 | 2015 | 112 | 0.030 |
Why?
|
| Family Health | 2 | 2007 | 45 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 23 | 0.030 |
Why?
|
| Sample Size | 1 | 2014 | 27 | 0.030 |
Why?
|
| Bone Density | 1 | 2015 | 96 | 0.030 |
Why?
|
| Eating | 1 | 1994 | 34 | 0.030 |
Why?
|
| Collodion | 1 | 2013 | 1 | 0.030 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2013 | 1 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2013 | 3 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 85 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2013 | 11 | 0.030 |
Why?
|
| Angiotensin II | 1 | 1993 | 2 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 304 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2013 | 5 | 0.020 |
Why?
|
| Health Maintenance Organizations | 1 | 2014 | 403 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 1 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 24 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2015 | 256 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 228 | 0.020 |
Why?
|
| Lod Score | 1 | 2012 | 1 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 110 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 23 | 0.020 |
Why?
|
| Translational Medical Research | 1 | 2011 | 32 | 0.020 |
Why?
|
| Immunoblotting | 2 | 2003 | 2 | 0.020 |
Why?
|
| Glyburide | 1 | 2010 | 9 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 122 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2002 | 144 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2001 | 34 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2009 | 6 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2009 | 3 | 0.020 |
Why?
|
| Hemostasis, Surgical | 1 | 2009 | 2 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2009 | 16 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 70 | 0.020 |
Why?
|
| Tolbutamide | 2 | 2000 | 3 | 0.020 |
Why?
|
| Thymine | 1 | 2008 | 1 | 0.020 |
Why?
|
| Cytosine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2009 | 99 | 0.020 |
Why?
|
| Siblings | 1 | 2007 | 13 | 0.020 |
Why?
|
| San Francisco | 1 | 2007 | 62 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 20 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2007 | 23 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2007 | 4 | 0.020 |
Why?
|
| Los Angeles | 1 | 2007 | 150 | 0.020 |
Why?
|
| Postprandial Period | 1 | 2007 | 6 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 545 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2005 | 13 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2003 | 1 | 0.010 |
Why?
|
| 3T3-L1 Cells | 1 | 2003 | 2 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 3 | 0.010 |
Why?
|
| Proteins | 1 | 2003 | 15 | 0.010 |
Why?
|
| Medical Records | 1 | 2002 | 91 | 0.010 |
Why?
|
| Skinfold Thickness | 1 | 2001 | 18 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 10 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 18 | 0.010 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2001 | 55 | 0.010 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2001 | 38 | 0.010 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2000 | 3 | 0.010 |
Why?
|
| Central Nervous System | 1 | 2000 | 3 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 2000 | 8 | 0.010 |
Why?
|
| Sulfonylurea Compounds | 1 | 2000 | 32 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2000 | 18 | 0.010 |
Why?
|
| Air Pollutants, Radioactive | 1 | 1999 | 1 | 0.010 |
Why?
|
| Carcinogens, Environmental | 1 | 1999 | 1 | 0.010 |
Why?
|
| Uranium | 1 | 1999 | 1 | 0.010 |
Why?
|
| Half-Life | 1 | 1999 | 5 | 0.010 |
Why?
|
| Mining | 1 | 1999 | 2 | 0.010 |
Why?
|
| Radon | 1 | 1999 | 2 | 0.010 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1999 | 6 | 0.010 |
Why?
|
| Causality | 1 | 1999 | 35 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1999 | 57 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1999 | 346 | 0.010 |
Why?
|
| Contraindications | 1 | 1998 | 14 | 0.010 |
Why?
|
| Fetal Diseases | 1 | 1998 | 8 | 0.010 |
Why?
|
| Morbidity | 1 | 1998 | 59 | 0.010 |
Why?
|
| Carotid Stenosis | 1 | 1998 | 8 | 0.010 |
Why?
|
| Forecasting | 1 | 1998 | 68 | 0.010 |
Why?
|
| Prognosis | 1 | 1999 | 609 | 0.010 |
Why?
|
| Heart Septum | 1 | 1996 | 1 | 0.010 |
Why?
|
| Ouabain | 1 | 1996 | 1 | 0.010 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 1996 | 1 | 0.010 |
Why?
|
| Heart Atria | 1 | 1996 | 3 | 0.010 |
Why?
|
| Biological Transport | 1 | 1996 | 2 | 0.010 |
Why?
|
| Azetidines | 1 | 1996 | 2 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1996 | 7 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 1996 | 7 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1996 | 7 | 0.010 |
Why?
|
| Sodium | 1 | 1996 | 14 | 0.010 |
Why?
|
| Potassium | 1 | 1996 | 14 | 0.010 |
Why?
|
| Calcium | 1 | 1996 | 30 | 0.010 |
Why?
|
| Age of Onset | 1 | 1995 | 74 | 0.010 |
Why?
|
| Intrauterine Device Expulsion | 1 | 1994 | 5 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 278 | 0.010 |
Why?
|
| Renal Circulation | 1 | 1993 | 1 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 9 | 0.010 |
Why?
|